Disease · EFO_0009910
chronic lung disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. chronic lung disease. Diseases, record EFO_0009910. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009910
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- chronic lung disease
- Open Targets ID
- EFO_0009910
- Highest stage of its drugs
- Phase 3, for 6 of its 15 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs15
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BERACTANT | CHEMBL1201624 | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets | |
| PORACTANT ALFA | CHEMBL1201622 | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets | |
| AZITHROMYCIN | CHEMBL529 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OXYGEN | CHEMBL1234886 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SILDENAFIL | CHEMBL192 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CHLOROTHIAZIDE | CHEMBL842 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NITRIC OXIDE | CHEMBL1200689 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SPIRONOLACTONE | CHEMBL1393 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ACETAMINOPHEN | CHEMBL112 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 15
See all 15 drugsTargets13
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PTGS1 | Cyclooxygenase | 3 | Cyclooxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 3 | Cyclooxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| FAAH | Fatty-acid amide hydrolase 1 | 1 | Anandamide amidohydrolase inhibitor | Phase 2 | https://conductscience.org/library/genes/2166 | Drugs and targets |
| GUCY1A1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 2/3 | https://conductscience.org/library/genes/2982 | Drugs and targets |
| GUCY1A2 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 2/3 | https://conductscience.org/library/genes/2977 | Drugs and targets |
| GUCY1B1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 2/3 | https://conductscience.org/library/genes/2983 | Drugs and targets |
| IL1R1 | Interleukin-1 receptor type 1 | 1 | Interleukin-1 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/3554 | Drugs and targets |
| NR3C2 | Mineralocorticoid receptor | 1 | Mineralocorticoid receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/4306 | Drugs and targets |
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | 1 | Phosphodiesterase 5A inhibitor | Phase 3 | https://conductscience.org/library/genes/8654 | Drugs and targets |
1 to 10 of 13
See all 13 targetsTrials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00233324 | Surfactant Positive Airway Pressure and Pulse Oximetry Trial | Phase 3 | 1,316 | 2014-12-05 | Infant, Newborn, Diseases, Other Preterm Infants, Infant, Small for Gestational Age, Premature Birth, Bronchopulmonary Dysplasia, Retinopathy of Prematurity | OXYGEN | Its record names the disease | ClinicalTrials.gov |
| NCT00515281 | Inhaled Nitric Oxide and Neuroprotection in Premature Infants | Phase 2/3 | 273 | 2024-10-17 | Prematurity, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Periventricular Leukomalacia | NITRIC OXIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04347720 | Canadian National PDA Treatment Study | 1,663 | Patent Ductus Arteriosus, Extreme Prematurity | ACETAMINOPHEN, IBUPROFEN, INDOMETHACIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT00011362 | Dexamethasone Therapy in VLBW Infants at Risk of CLD | Phase 3 | 371 | Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov | |
| NCT02426112 | Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children | Phase 3 | 347 | Chronic Lung Disease, HIV Infection | AZITHROMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07447739 | Can Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively? | Phase 2 | 100 | Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD) | BETAMETHASONE | Its record names the disease | ClinicalTrials.gov | |
| NCT02099955 | Vitamin D Deficiency and Replacement on Pulmonary and Endocrine Function in SCI | Phase 1/2 | 88 | Spinal Cord Injury, Vitamin D Deficiency | CHOLECALCIFEROL | Its record names the disease | ClinicalTrials.gov | |
| NCT02819414 | Paracetamol Treatment of the Borderline Significant PDA | Phase 2 | 80 | Patent Ductus Arteriosus | ACETAMINOPHEN | Its record names the disease | ClinicalTrials.gov | |
| NCT01721655 | Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease | Phase 2/3 | 40 | Chronic Lung Disease, Bronchopulmonary Dysplasia | CHLOROTHIAZIDE, SPIRONOLACTONE | Its record names the disease | ClinicalTrials.gov | |
| NCT07254000 | Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants | Phase 2 | 24 | Premature Infants, Very Premature Infants, Inflammation | ANAKINRA | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| CPAP vs Surfactant: Survival Without Bronchopulmonary Dysplasia (BPD) | 346 of 663 | 320 of 653 | 1,316 | NCT00233324 | Trial comparisons |
| Lower Oxygen Saturation Target vs Higher Oxygen Saturation Target: Survival Without Severe Retinopathy of Prematurity (ROP) (Threshold Disease or the Need for Surgery) | 434 of 605 | 418 of 616 | 1,221 | NCT00233324 | Trial comparisons |
| INO Control (Short iNO) vs INO Treatment (Long iNO): Supplemental Oxygen Use | 30 of 138 | 28 of 135 | 273 | NCT00515281 | Trial comparisons |
| INO Control (Short iNO) vs INO Treatment (Long iNO): Death | 19 of 138 | 13 of 135 | 273 | NCT00515281 | Trial comparisons |
| INO Control (Short iNO) vs INO Treatment (Long iNO): deaths from any cause | 19 of 138 | 13 of 135 | 273 | NCT00515281 | Trial comparisons |
| INO Control (Short iNO) vs INO Treatment (Long iNO): Bronchopulmonary Dysplasia (BPD) or Death | 65 of 138 | 83 of 135 | 273 | NCT00515281 | Trial comparisons |
| INO Control (Short iNO) vs INO Treatment (Long iNO): Bronchopulmonary Dysplasia | 51 of 138 | 71 of 135 | 273 | NCT00515281 | Trial comparisons |
| INO Control (Short iNO) vs INO Treatment (Long iNO): serious adverse events | 53 of 138 | 61 of 135 | 273 | NCT00515281 | Trial comparisons |
| INO Control (Short iNO) vs INO Treatment (Long iNO): BPD or Death in Black Infants | 50 of 99 | 53 of 91 | 190 | NCT00515281 | Trial comparisons |
| INO Control (Short iNO) vs INO Treatment (Long iNO): BPD or Death in Infants Weighing 750-999g | 20 of 43 | 36 of 44 | 87 | NCT00515281 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials36
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0009910
GET https://conductscience.org/api/diseases/v1/EFO_0009910/papers?page=2